# Datasets for post-market surveillance

Discover comprehensive, trusted, machine-readable data to:

- Screen for adverse drug events with high-precision data points.
- Build and train algorithms to sort literature into relevant and non-relevant sets based on drug safety signals.
- Guide medical device post-market surveillance.
- Explore, analyse, query and manage underutilized source of safety information.









8,300 journals (including 3.3K not found in Medline)



**5.1M** conference abstracts



therapeutic areas with



**30M**FDA and EMA
post-market
reports



2.8M
extracted safety
& adverse
event data

## Biomedical data

- Structured biomedical literature, extracted from 8.3k journals (including 3.3k not found in Medline).
- 5.1M conference abstracts from 11.5k conferences (not found in Medline).
- 95 countries represented in journal selection.

# Therapeutic area full-text data

- Therapy areas include cardiovascular, endocrine, diabetes & metabolism, oncology and more.
- Structured and semi-structured data from life science journals.
- Organized by therapeutic area (rather than journal collection) for comprehensive view.

# **Drug safety data**

- Structured data extracted from FDA, EMA regulatory documents and literature articles.
- 2.3M extracted PK data records.
- 4.1M extracted efficacy data on clinical trials from regulatory packages.
- 22M FDA FAERS.
- 2.8M extracted safety and adverse event data.



### The elements of data quality

- Peer reviewed, highly cited article content.
- Biomedical data structured with Emtree –
   as recommended by EMA Guideline on Good
   Pharmacovigilance Practices (GVP), UK's NICE
   Interim Clinical Guideline Surveillance Process
   and Methods Guide and more.
- Human expertise in manual excerption, data science and the scientific domain ensures data accuracy.
- Continual investment in AI/ML excerption drives quality data.
- Clear provenance for evidence-based decisions.
- Semantic enrichment using ontologies adhering to public standards and custom vocabularies.



# Case study

Accelerate safety literature reviews without loss of precision and recall

Discover how Elsevier data is used to detect the presence or absence of reported safety signals in a drug.

Read the full story

### Flexible delivery into workflows

Supporting interoperability with your workflows. Enhanced support (consultancy and scripts) for effective data integration.



API







"The deep indexing of Emtree is a really important piece of the search."

Knowledge Manager, US Medical Technologies Organization

"An essential resource for post-market monitoring [...] I can't imagine doing that kind of safety monitoring without it."

Senior Researcher, UK



Improve your data foundations – learn more: elsevier.com/solutions/datasets